1. Home
  2. UFCS vs MLYS Comparison

UFCS vs MLYS Comparison

Compare UFCS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

N/A

Current Price

$54.08

Market Cap

1.4B

Sector

Finance

ML Signal

N/A

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$28.03

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UFCS
MLYS
Founded
1946
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
2.5B
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
UFCS
MLYS
Price
$54.08
$28.03
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$40.50
$48.67
AVG Volume (30 Days)
113.9K
1.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
2.01%
N/A
EPS Growth
87.45
37.43
EPS
2.45
N/A
Revenue
$1,386,412,000.00
N/A
Revenue This Year
$11.80
N/A
Revenue Next Year
$8.77
N/A
P/E Ratio
$22.13
N/A
Revenue Growth
10.62
N/A
52 Week Low
$29.75
$22.30
52 Week High
$56.74
$47.65

Technical Indicators

Market Signals
Indicator
UFCS
MLYS
Relative Strength Index (RSI) 50.55 52.21
Support Level $52.21 $25.56
Resistance Level $55.12 $31.36
Average True Range (ATR) 1.38 1.58
MACD -0.09 0.11
Stochastic Oscillator 41.44 45.15

Price Performance

Historical Comparison
UFCS
MLYS

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: